Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.39 |
| ▸ | CA2 | P00918 | 17/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054943 | 0.77 | — | — | |
| SCHEMBL19091682 | 0.75 | RIPK1 (0.37) | MEN1KMT2A | |
| Creatine SCHEMBL27979093 | 0.75 | NOS3 (0.46) | CA1CA2NOS3NOS1NOS2 | |
| SCHEMBL14375590 | 0.75 | CHRM1 (0.38) | KMT2A | |
| Creatine SCHEMBL21567 | 0.75 | — | — | |
| Creatine SCHEMBL30063981 | 0.75 | — | — | |
| SCHEMBL430835 | 0.75 | — | — | |
| Creatine SCHEMBL4007614 | 0.75 | NOS3 (0.46) | CA1CA2NOS3NOS1NOS2 | |
| SCHEMBL20609595 | 0.74 | — | — | |
| SCHEMBL4587557 | 0.74 | CA1 (0.36) | CA1CA2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702448-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702448-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210169970-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2021-06-10 | — | — | US | disclosed |
| US-10960046-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | RHYTHM PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10954268-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210061852-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20180194803-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9845339-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845339-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140329743-A1 | Method of Treating Melanocortin-4 Receptor-Associated Disorders in Heterozygous Carriers | RHYTHM PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169970-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | CA1 4877/4885CA2 4778/4885NOS3 3560/4885 |
| US-10960046-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | MC4R, MC5R, MC3R | CA1 4865/4885CA2 4644/4885NOS3 3393/4885 |
| US-20140329743-A1 | Method of Treating Melanocortin-4 Receptor-Associated Disorders in Heterozygous Carriers | MC4R, MC1R, MC2R | CA1 4565/4885CA2 3705/4885NOS3 4305/4885 |
| US-20210061852-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | MC4R, MC1R, MC2R | CA1 4760/4885CA2 3814/4885NOS3 4488/4885 |
| US-11702448-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | MC4R, MC1R, MC2R | CA1 4760/4885CA2 3814/4885NOS3 4488/4885 |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | CA1 2891/4885CA2 2549/4885NOS3 1273/4885 |
| US-20180194803-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | MC4R, MC1R, MC2R | CA1 4760/4885CA2 3814/4885NOS3 4488/4885 |
| US-10954268-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | MC4R, MC1R, MC2R | CA1 4760/4885CA2 3814/4885NOS3 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.